SBIR/STTR Research Award
IN VIVO ASSAYS OF ANTIFUNGAL DRUG TARGETS
Award amount
$94,612Program and phase
SBIR · Phase IAward year
2002Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CLARITY BIOSCIENCES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Provided by applicant): Patients with weakened immune systems are
at highest risk for life-threatening opportunistic fungal infections. There are
a limited number of antifungal drugs currently available to treat these
patients. Drug resistance and toxicity now threatens to shorten the usefulness
of these drugs. In phaseI of this project we will create and validate an in
vivo assay for the identification of novel antifungal drug targets. The assay
will provide a means to monitor the effect of compounds on the function of the
drug targets. The assay will be exploited in Phase II to identify candidate
compounds that inhibit the function of the drug target. The candidate drugs
will be further tested in clinical trials then commercialized.
PROPOSED COMMERCIAL APPLICATION:
The in vivo assay developed in thie project will be used in Phase II to identify candidate
antifungal drugs. These drugs will be commercialized following sucessful clinical trials to
demonstrate their safety and efficacy.
Technology keywords
Not reported